BETHESDA, Md., March 16, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO). Taking note of the recent unusual activity in the Company's stock, Northwest Biotherapeutics (NWBT) commented today that it is not aware of any basis relating to the Company or its products or programs.
The Company is continuing to move forward with the trial-related activities for its large, 240-patient clinical trial for GBM brain cancer. The patients treated with NWBT's DCVax treatment in the prior clinical trials have shown strikingly positive results in the ongoing long-term follow-up after those trials. The Company has developed program activities outside the US to complement its program activities in the US. The Company believes that the recent unusual activity in its stock does not reflect the fundamentals of the Company.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company is developing dendritic cell-based vaccines. The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal form of brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.
For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.
Statements made in this news release that are no
|SOURCE Northwest Biotherapeutics|
Copyright©2010 PR Newswire.
All rights reserved